BioHarvest News
14 articles
growth-positive
BioHarvest Sciences positioned for ‘legacy year’ in 2025, building on momentum with new innovations and strategic collaborations
BioHarvest Sciences Inc. is set to leverage key trends in the health and wellness industry, focusing on sustainability, longevity, and plant-based innovation. The company experienced significant growth in 2024, particularly in its direct-to-consumer business, driven by its VINIA product line. BioHarvest plans to expand its product offerings in 2025, including new beverage options and VINIA Super-Chews. The company also aims to strengthen its CDMO services, having formed a key partnership with Tate & Lyle to develop sugar-free sweeteners. BioHarvest anticipates further partnerships in cosmetics, nutraceuticals, and pharmaceuticals, positioning 2025 as a pivotal year for growth and innovation.
Product StageCustomersPartners
growth-positive
BioHarvest Sciences Begins Trading on the Nasdaq Global Market
BioHarvest Sciences Inc., a leader in Botanical Synthesis, has announced its shares will begin trading on the Nasdaq Global Market under the ticker symbol BHST. This move is seen as a significant milestone for the company, expected to elevate its public profile, improve liquidity, and expand its shareholder base. The company will continue trading on the Canadian Securities Exchange. BioHarvest is known for its patented technology platform that grows active ingredients in plants without the need to grow the plant itself. The company is involved in developing therapeutic solutions and nutraceutical products. BioHarvest will release its third-quarter financial results on November 25, 2024, followed by an investor conference call.
Public Trading
BioHarvest Sciences announces a private placement of up to USD $5 million
growth-positive
BioHarvest Sciences Announces a Private Placement of up to CAD $8M of Convertible Notes to Grow Core Business - BioHarvest Sciences
BioHarvest Sciences Inc. has announced a private placement of up to CAD $8 million of two-year convertible notes. The funds raised will primarily support the companys growth in its polyphenols/antioxidants vertical and its R&D program for potentially providing Active Pharmaceutical Ingredients (APIs) to the pharmaceutical industry. The company has provided revenue guidance for 2023 and aims to achieve cash flow breakeven in Q4/2023. BioHarvest Sciences Inc. is focusing on the growth of its core polyphenols business, the development of pharmaceutical-grade cannabis compositions, and the expansion of its clinical studies. The private placement of the notes will be available to qualified investors.
Investment
growth-positive
BIOHARVEST SCIENCES ANNOUNCES CLINICAL STUDY IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED OPTIC NEURITIS - BioHarvest Sciences
BioHarvest Sciences Inc. has announced a collaboration with the International Neurorehabilitation Institute (INI) to perform a clinical trial to assess the capacity of its RGC composition to promote eye health. The study will evaluate the impact of RGC on multiple sclerosis (MS)-related optic neuritis driven by inflammation. The company aims to elucidate the mechanisms through which RGC impacts the disease by measuring anti-oxidative, detoxifying, and inflammatory biomarkers. The study is the first human clinical study to evaluate the combination of health-promoting phytonutrients for the promotion of eye health. The collaboration with INI marks an important step for BioHarvest in creating science-based therapeutic solutions.
PartnersCustomers
growth-positive
BioHarvest Sciences Inc. Delivers Record Q2 Sales Order Results with Progress on All Fronts
BioHarvest Sciences Inc. announces an increase in sales orders in Q2/2021 compared to previous quarters, with a 10% increase over Q1/2021 and an 840% increase over Q2/2020. The customer count also grew by 5% in Q2/2021. The direct-to-consumer launch in the USA is showing promising metrics. The company has achieved milestones in optimizing plant biology and commercializing cannabis-based products. BioHarvests BioFarming technology has demonstrated efficiency and reliability in producing cannabis trichomes. The CEO expresses optimism about the companys prospects and pipeline of nutraceutical and cannabis products. BioHarvest Sciences Inc. is a developer and owner of the BioFarming technology, aiming to generate revenue in the nutraceutical and cannabis markets.
CustomersInvestment
growth-positive
Bioharvest Sciences Inc.'s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years
BioHarvest Sciences Inc. has achieved a significant milestone in its production of Cannabinoids using its BioFarming technology. The companys technology has reduced the production cycle time for Cannabis from 14-23 weeks to 3-4 weeks, allowing for more frequent harvests. The technology bypasses the seeding and vegetative stages, resulting in higher efficiency and consistency. BioHarvest Sciences Inc. plans to commercialize its Cannabis-based products in the first half of 2022. The achievement of using the same cell reservoir for two years demonstrates the robustness of the technology. The company invites interested investors and media to a shareholder update webinar on July 8, 2021.
Expand
growth-positive
מעוף, חזון ותעוזה עסקית בימי קורונה - חברת BioHarvest חתמה על הסכם ייצור עם חברת "שוגארט" מיבנה
BioHarvest, a Canadian company, has entered into a partnership with Sugart to implement its BioFarming technology. The company aims to operate in the nutraceuticals and medical cannabis markets, both estimated to be worth billions of dollars. As per the agreement, BioHarvest will finance the purchase of equipment needed to implement the BioFarming technology and the necessary upgrades in Sugarts industrial complex. Sugart will establish and operate a factory for the production, packaging, and distribution of BioHarvests nutraceutical products.
PartnersExpand
growth-positive
Canna-V-Cell Announces Business Combination with its Controlling Shareholder BioHarvest Ltd. ("Bio Harvest")
Canna-V-Cell Sciences Inc. has announced a merger agreement with its 46% controlling shareholder BioHarvest Ltd. and its wholly owned Israeli subsidiary Biofarming Ltd. Under the terms of the agreement, Canna V will acquire 100% of BioHarvest by issuing 299,200,000 common shares at a deemed price of $0.15 per share to the shareholders of BioHarvest. The acquisition price is based on a valuation report estimating the value of BioHarvest Ltd. to be between $33,700,000 U.S. and $34,600,000 U.S. The acquisition will give Canna V ownership of 14 patents and patents pending held by Bio Harvest.
AcquisitionInvestment
growth-positive
BioHarvest Ltd. Announces Preliminary Clinical Results of VINIA™ on Type 2 Diabetes
BioHarvest, an Israeli biotechnology company, has developed a technology that enables the production of safe and functional bio-food with phytonutrients in their original state. Their flagship product, VINIA, is a red grape powder that contains polyphenols, including resveratrol. VINIA has undergone scientific studies that support its claims to support heart health and promote healthy blood circulation. A recent study has shown that VINIA may positively affect patients with Type 2 diabetes. BioHarvest plans to conduct additional studies to explore the potential utility of VINIA in improving glucose metabolism. BioHarvest is the worlds first and only commercial entity to produce biofoods at an industrial scale while maintaining their original chemical structure consistently throughout production.
Customers
growth-positive
1,000 red grapes in a single teaspoon
The article discusses BioHarvest, a company that produces a red-grape extract called Vinya. The extract contains resveratrol, which has been proven to have health benefits. BioHarvests product is unique because it contains a synergy of over a hundred active components found in grapes, making it more effective than resveratrol extract alone. The company uses hydroponic farming to grow grapes in a lab, allowing for full control of the process and a shorter life cycle. The product has been through clinical trials and has received FDA approval for its health claims. BioHarvest plans to launch the product in the US through online sales. The company has received investments from Zaki Rakib, Canadas Greensway Fund, and other private investors. BioHarvest aims to become a significant company in Israel and expand its product offerings in the future.
InvestmentExpand
growth-positive
You don't need Vinia to avoid Wine Hangovers
BioHarvest, an Israeli biotechnology company, has developed a patented platform to grow and bio-harvest fruit cell cultures. The companys unique technology allows for the production of safe and clinically researched super-foods rich in phytonutrients. Their first commercial product, red grape cell powder called Vinia, has been designated as a novel food in Israel and has beneficial effects on cardiovascular disease and metabolic conditions. Vinia is being launched and goes on sale in the US, but it is quite expensive. The daily dose of the dietary supplement retails for $120. The article discusses the health benefits of wine and questions the need for a dietary supplement like Vinia.
Customers
growth-negative
Broadway News Broadway Tickets & Videos Broadway World
Lookingglass Theatre Company has announced a programming pause and staff reduction. The article discusses various theater-related news and events.
Layoffs
This firm harvests hope
